Middle-term use of Cinacalcet in paediatric dialysis patients
- 1 January 2010
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 25 (1), 143-148
- https://doi.org/10.1007/s00467-009-1294-7
Abstract
The effects of the calcimimetic drug Cinacalcet were assessed in six children with uncontrolled hyperparathyroidism secondary to stage 5 chronic kidney disease (CKD). Data were collected retrospectively regarding bone biochemistry and medications. Patients were between the ages of 11 months and 14 years on commencing Cinacalcet at initial doses of 0.4–1.4 mg/kg. Treatment, which was well tolerated in the majority and still on going in five patients, was for periods ranging between 3 months and 3 years. All six cases saw at least an 86% reduction in serum parathyroid hormone (PTH). Hypophosphataemia and/or hypocalcaemia were observed in three cases. Overall, achievement of UK Renal Association targets for corrected calcium (Ca), phosphate (P) and the calcium × phosphate product (Ca × P) were unaffected. We conclude that Cinacalcet is an effective treatment for correcting and sustaining correction of uncontrollable PTH levels seen in a difficult group of patients. Importantly, it has allowed the avoidance of parathyroidectomy for a significant time period in all cases. There remain questions about the effect of Cinacalcet on linear growth amongst paediatric dialysis patients, and future studies should aim to address this.Keywords
This publication has 29 references indexed in Scilit:
- New strategies for the treatment of hyperparathyroidism incorporating calcimimeticsExpert Opinion on Pharmacotherapy, 2008
- Cinacalcet HCl (Sensipar/ Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidismClinical Nephrology, 2007
- Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal DialysisJournal of the American Society of Nephrology, 2005
- Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HClKidney International, 2005
- Vascular calcification: A stiff challenge for the nephrologistKidney International, 2004
- Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trialsPediatric Nephrology, 2003
- Effects of Ca2‐sensing receptor activation in the growth plateThe FASEB Journal, 2003
- Catch-up growth with normal parathyroid hormone levels in chronic renal failurePediatric Nephrology, 2003
- Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapyKidney International, 1994
- Optimal correction of acidosis changes progression of dialysis osteodystrophyKidney International, 1989